A low dicer expression is associated with resistance to 5-FU-based chemoradiotherapy and a shorter overall survival in patients with oral squamous cell carcinoma

Journal of Oral Pathology and Medicine

Volumn 43, Issue 5, 2014, Pages 350-356

  Kawahara, Kenta ^a   Nakayama, Hideki ^a   Nagata, Masashi ^a   Yoshida, Ryoji ^a   Hirosue, Akiyuki ^a   Tanaka, Takuya ^a   Nakagawa, Yoshihiro ^a   Matsuoka, Yuichiro ^a   Kojima, Taku ^a   Takamune, Yasuo ^a   Yoshitake, Yoshihiro ^a   Hiraki, Akimitsu ^a   Shinohara, Masanori ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Dicer; MicroRNA; Oral squamous cell carcinoma; Prognosis; Resistance

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; DEAD BOX PROTEIN; DICER1 PROTEIN, HUMAN; DROSHA PROTEIN, HUMAN; FLUOROURACIL; RIBONUCLEASE III; TUMOR MARKER;

ADULT; AGED; BIOPSY; CANCER GRADING; CANCER STAGING; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; DISEASE FREE SURVIVAL; DRUG RESISTANCE; ENZYMOLOGY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MOUTH NEOPLASMS; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TONGUE NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; BIOPSY; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; DEAD-BOX RNA HELICASES; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; RIBONUCLEASE III; SURVIVAL RATE; TONGUE NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84898771866     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/jop.12140     Document Type: Article

References (42)

1. Shah JP, Gil Z. Current concepts in management of oral cancer-surgery. Oral Oncol 2009; 45: 394-401.
2. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010; 9: 775-89.
3. Merritt WM, Bar-Eli M, Sood AK. The dicey role of Dicer: implications for RNAi therapy. Cancer Res 2010; 70: 2571-4.
4. Akao Y, Noguchi S, Iio A, et al. Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells. Cancer Lett 2011; 300: 197-204.
5. Cowland JB, Hother C, Gronbaek K. MicroRNAs and cancer. APMIS 2007; 115: 1090-106.
6. Du T, Zamore PD. Beginning to understand microRNA function. Cell Res 2007; 17: 661-3.
7. Kovalchuk O, Filkowski J, Meservy J, et al. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 2008; 7: 2152-9.
8. Wu BH, Xiong XP, Jia J, et al. MicroRNAs: new actors in the oral cancer scene. Oral Oncol 2011; 47: 314-9.
9. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-8.
10. Gaur A, Jewell DA, Liang Y, et al. Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res 2007; 67: 2456-68.
11. Kumar MS, Lu J, Mercer KL, et al. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 2007; 39: 673-7.
12. Shimosato Y, Oboshi S, Baba K. Histological evaluation of effects of radiotherapy and chemotherapy for carcinomas. Jap J Clin Oncol 1971; 1: 19-35.
13. Faggad A, Budczies J, Tchernitsa O, et al. Prognostic significance of Dicer expression in ovarian cancer-link to global microRNA changes and oestrogen receptor expression. J Pathol 2010; 220: 382-91.
14. Zheng T, Wang J, Chen X, et al. Role of microRNA in anticancer drug resistance. Int J Cancer 2010; 126: 2-10.
15. Kutanzi KR, Yurchenko OV, Beland FA, et al. MicroRNA-mediated drug resistance in breast cancer. Clinical Epigenetics 2011; 2: 171-85.
16. Karube Y, Tanaka H, Osada H, et al. Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Sci 2005; 96: 111-5.
17. Merritt WM, Lin YG, Han LY, et al. Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med 2008; 359: 2641-50.
18. Grelier G, Voirin N, Ay AS, et al. Prognostic value of Dicer expression in human breast cancers and association with the mesenchymal phenotype. Br J Cancer 2009; 101: 673-83.
19. Guo X, Liao Q, Chen P, et al. The microRNA-processing enzymes: Drosha and Dicer can predict prognosis of nasopharyngeal carcinoma. J Cancer Res Clin Oncol 2012; 138: 49-56.
20. Zighelboim I, Reinhart AJ, Gao F, et al. DICER1 expression and outcomes in endometrioid endometrial adenocarcinoma. Cancer 2011; 117: 1446-53.
21. Lin RJ, Lin YC, Chen J, et al. microRNA signature and expression of Dicer and Drosha can predict prognosis and delineate risk groups in neuroblastoma. Cancer Res 2010; 70: 7841-50.
22. Chiosea S, Jelezcova E, Chandran U, et al. Up-regulation of dicer, a component of the MicroRNA machinery, in prostate adenocarcinoma. Am J Pathol 2006; 169: 1812-20.
23. Faber C, Horst D, Hlubek F, et al. Overexpression of Dicer predicts poor survival in colorectal cancer. Eur J Cancer 2011; 47: 1414-9.
24. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259-69.
25. Hammond SM. MicroRNAs as oncogenes. Curr Opin Genet Dev 2006; 16: 4-9.
26. Zhang B, Pan X, Cobb GP, et al. microRNAs as oncogenes and tumor suppressors. Dev Biol 2007; 302: 1-12.
27. Kozaki K, Imoto I, Mogi S, et al. Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res 2008; 68: 2094-105.
28. Bu Y, Lu C, Bian C, et al. Knockdown of Dicer in MCF-7 human breast carcinoma cells results in G1 arrest and increased sensitivity to cisplatin. Oncol Rep 2009; 21: 13-7.
29. Kuang Y, Cai J, Li D, et al. Repression of Dicer is associated with invasive phenotype and chemoresistance in ovarian cancer. Oncol Lett 2013; 5: 1149-54.
30. Weidhaas JB, Babar I, Nallur SM, et al. MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Res 2007; 67: 11111-6.
31. Childs G, Fazzari M, Kung G, et al. Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma. Am J Pathol 2009; 174: 736-45.
32. Chiosea SI, Barnes EL, Lai SY, et al. Mucoepidermoid carcinoma of upper aerodigestive tract: clinicopathologic study of 78 cases with immunohistochemical analysis of Dicer expression. Virchows Arch 2008; 452: 629-35.
33. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer 2011; 11: 393-410.
34. Ho JJ, Metcalf JL, Yan MS, et al. Functional importance of Dicer protein in the adaptive cellular response to hypoxia. J Biol Chem 2012; 287: 29003-20.
35. Jubb AM, Buffa FM, Harris AL. Assessment of tumour hypoxia for prediction of response to therapy and cancer prognosis. J Cell Mol Med 2010; 14: 18-29.
36. Semenza GL. Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today 2007; 12: 853-9.
37. Murchison EP, Partridge JF, Tam OH, et al. Characterization of Dicer-deficient murine embryonic stem cells. Proc Natl Acad Sci U S A 2005; 102: 12135-40.
38. Murchison EP, Stein P, Xuan Z, et al. Critical roles for Dicer in the female germline. Genes Dev 2007; 21: 682-93.
39. Tang F, Kaneda M, O'carroll D, et al. Maternal microRNAs are essential for mouse zygotic development. Genes Dev 2007; 21: 644-8.
40. Cuellar TL, Davis TH, Nelson PT, et al. Dicer loss in striatal neurons produces behavioral and neuroanatomical phenotypes in the absence of neurodegeneration. Proc Natl Acad Sci U S A 2008; 105: 5614-9.
41. Chong MM, Zhang G, Cheloufi S, et al. Canonical and alternate functions of the microRNA biogenesis machinery. Genes Dev 2010; 24: 1951-60.
42. Shi XB, Tepper CG, Devere White RW. Cancerous miRNAs and their regulation. Cell Cycle 2008; 7: 1529-38.